drugset / Trial / NCT00583622
Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if bevacizumab, when given in combination with gemcitabine, docetaxel, melphalan and carboplatin, or with topotecan, cyclophosphamide and melphalan (if you are older than 60 or have an allergy to carboplatin), can help to control ovarian cancer during a stem cell transplant. The safety of this drug combination will also be studied.
Timeline
- Start
- 2007-12
- Primary completion
- 2012-01
- Completion
- 2012-01
Outcome
Outcome not reported
Stopped (Enrollment): “Slow Accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Carboplatin | Small molecule | 333 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 300 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 1800 mg/m2 | Intravenous |
| Subject | Melphalan | Small molecule | 50 mg/m2 | Intravenous |